Clinical trial register · European Union · CTIS

Clinical Trials in France, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV

Source: EMA Clinical Trials Information System (CTIS). Showing the 2557 most recently authorised of 12788 total CTIS records — a stated recency window, not the full historical archive. Synced 07 Nov 2026, 03:17 UTC

2557

Shown in this register

most recently authorised

12,788

Total on CTIS

full historical archive

789

Phase III

within the shown window

Top member states

Spain 1074 France 933 Germany 893 Italy 777 Poland 614 Netherlands 544

Narrow the registerReset

Search within results

Phase

Lead sponsor

Member state

All 28 states

Trials with a site in France

Phase

Study

Lead sponsor

Area

Member states

Decision

Phase IV

A Single Arm, Multicenter Open-Label Interventional Collaborative Study to Evaluate the Efficacy of Upadacitinib re-induction therapy in patients with Ulcerative Colitis who lost response to 30 mg maintenance dose - Re-induCtiOn with UPadacitinib (ReCOUP Study)

2026-526174-16-00Ulcerative Colitis

DrugUpadacitinib

i-GETAID

Digestive System Diseases

France

06/11/2026

Phase IV

Evaluation of the efficacy of sublingual sufentanil (Dzuveo®, prescribed as rescue analgesia for acute postoperative pain) on the quality of health recovery after surgery: a randomized, controlled, multicenter, open-label trial against an active comparator (SUBLIME)

2026-527137-64-00Operated on in a surgical department for a procedure whose …

DrugSufentanil

Les Hopitaux Universitaires De Strasbourg

Not possible to specify

France

02/11/2026

Phase IV

An exploratory double-blind randomized placebo-controlled trial to evaluate the effect of ARTENSIUM® cream in the relief of pain in patients with knee osteoarthritis

2026-527647-18-00Knee osteoarthritis is a chronic degenerative joint disease…

Boiron

Musculoskeletal Diseases

France

06/10/2026

Phase IV

PRIMO : Precision immunosuppressive drug monitoring in liver transplantation: a randomized control trial

2025-523563-38-00Immunosuppressive treatment in the context of liver transpl…

DrugTacrolimus

Centre Hospitalier Universitaire De Rennes

Digestive System Diseases

France

01/10/2026

Phase IV

Pharmacokinetic study of pembrolizumab and its impact on immunity and the tumor microenvironment, which may explain the efficacy of post-immunotherapy chemotherapy - CPI

2026-526866-26-00Non-small cell lung cancer (NSCLC) and Head and neck squamo…

DrugsCetuximab·Gemcitabine·Paclitaxel·Bevacizumab

Centre Antoine Lacassagne

Neoplasms

France

30/09/2026

Phase IV

A phase IV randomised, parallel-group, double-blinded, placebo-controlled, trial evaluating the efficacy of the tree SLIT-tablet in adolescents (12-17 years of age) with allergic rhinitis/allergic rhinoconjunctivitis induced by birch pollen using an environmental exposure unit.

2026-526861-88-00Moderate to severe allergic rhinitis/allergic rhinoconjunct…

Alk-Abello A/S

Immune System Diseases

France

21/09/2026

Phase IV

AIRITY: A hybrid cross-sectional and prospective study to assess patient characteristics, disease burden, disease control, phenotypes, endotypes, and outcomes in a real-world setting in patients with asthma

2025-524916-13-00Asthma

Sanofi-Aventis Recherche & Developpement

Respiratory Tract Diseases

France, Spain, Germany, Italy

09/09/2026

Phase IV

Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy _ POG

2025-523610-83-00Elderly patients (>70 years old) presenting with cancer and…

DrugsBrigatinib·Pazopanib·Sunitinib·Alectinib

Institut Gustave Roussy

Immune System Diseases

France

08/09/2026

Phase IV

A double-blind, randomised, 30-week placebo-controlled phase IV study to assess the efficacy and safety of osilodrostat in patients with hypertension caused by hypercortisolaemia due to Cushing’s Syndrome

2025-524649-28-00Cushing's syndrome

DrugOsilodrostat

Recordati AG

Hormonal diseases

Germany, Bulgaria, France, Romania, Italy, Poland, Spain

08/09/2026

Phase IV

HORUS-Cytomegalovirus Open Proof-of-concept Exploratory trial

2025-524845-28-00Cytomegalovirus infection in solid-organ transplant recipie…

DrugEverolimus

Centre Hospitalier Universitaire Vaudois

Virus Diseases

France, Spain

07/08/2026

Phase IV

Comparative study of two vaccination schedules for the subunit Herpes Zoster vaccine in Multiple Sclerosis and Neuromyelitis optica spectrum disease patients treated with anti-CD20 therapy: an open-label randomised controlled trial.

2025-525106-37-00Multiple Sclerosis and Neuromyelitis optica spectrum

DrugsOcrelizumab·Rituximab

Centre Hospitalier Universitaire De Toulouse

Nervous System Diseases

France

28/07/2026

Phase IV

ECETEP : Pilot study evaluating PSMA positron emission tomography for monitoring clinically significant prostate cancer after focal HIFU treatment

2026-525181-22-00prostate cancer

DrugPiflufolastat

Centre Hospitalier Universitaire De Toulouse

Diagnosis

France

25/06/2026

Phase IV

Sample Collection Study to Monitor the Risk of Malignancy Due to Insertional Oncogenesis in Early Onset Patients with Metachromatic Leukodystrophy Treated with OTL-200 in the Clinical Development Program

2025-522275-28-00Metachromatic leukodystrophy

Orchard Therapeutics (Europe) Limited

Musculoskeletal Diseases

Netherlands, Germany, Italy, Sweden, France

22/06/2026

Phase IV

STOP - Safety and efficacy of a STOPping strategy versus classical maintenance dose of JAK inhibitors in deep remission patients with ulcerative colitis: a randomized controlled trial

2026-525643-32-00ulcerative colitis

DrugsFilgotinib·Tofacitinib·Upadacitinib

Centre Hospitalier Regional De Marseille

Digestive System Diseases

France

17/06/2026

Phase IV

Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study (PRISMC3)

2025-524487-37-00Primary Immune Complex Membranoproliferative Glomerulonephr…

DrugPegcetacoplan

Swedish Orphan Biovitrum AB (publ)

Immune System Diseases

France, Italy, Spain, Germany, Austria, Belgium, Czechia

15/06/2026

Phase IV

PREP-ANCA - Comparison of a strategy based on clinic-biological surveillance versus pre-emptive treatment with rituximab in the event of ANCA (anti-neutrophil cytoplasm antibodies) repositivation in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)

2025-522049-23-00granulomatosis with polyangiitis and microscopic polyangiit…

DrugsPrednisone·Rituximab

Assistance Publique Hopitaux De Paris

Immune System Diseases

France

08/06/2026

Phase IV

ANTIMIDIS - Cefazolin mediastinal distribution using microdialysis

2025-521988-13-00Infection prophylaxis

DrugCefazolin

Assistance Publique Hopitaux De Paris

Bacterial Infections and Mycoses

France

05/06/2026

Phase IV

Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery: Impact on Postoperative Cardiovascular Outcomes – DISCO Study

2025-524395-30-00heart failure

DrugsMetformin·Dapagliflozin

Centre Hospitalier Universitaire De Toulouse

Cardiovascular Diseases

France

29/05/2026

Phase IV

Prognostic value of early assessment by ⁶⁸Ga-DOTATATE PET/CT for the treatment of well-differentiated grade 2 gastroenteropancreatic neuroendocrine tumors with ¹⁷⁷Lutetium-oxodotreotide.”

2025-524942-87-00Gastroenteropancreatic neuroendocrine tumors

Centre De Lutte Contre Le Cancer Eugene Marquis

Neoplasms

France

18/05/2026

Phase IV

A pragmatic, phase IV, randomized, open-label, multinational, multicentre, 2-arm parallel group, prospective study comparing efficacy and safety of Single Inhaler ICS/LABA/LAMA (beclometasone/formoterol fumarate/glycopyrronium bromide [87/5/9 pMDI {BD/FF/GB - 100/6/12.5 µg}]) vs Single Inhaler ICS/LABA (beclometasone dipropionate plus formoterol fumarate [200/6 pMDI {BD/FF - 200/6 µg}]) in asthma subjects.

2025-524289-56-00Asthma

Chiesi Farmaceutici S.p.A.

Respiratory Tract Diseases

Germany, Romania, Italy, Bulgaria, Poland, Slovakia, Spain, France

18/05/2026

Phase IV

OPTIMAL CARE WITH GUSELKUMAB IN CROHN’S DISEASE

2025-524573-16-00Crohn's disease

i-GETAID

Digestive System Diseases

France

16/04/2026

Phase IV

GLIFLOFASTER : EARLY GLIFLOZIN TREATMENT IN ELDERLY PATIENT HOSPITALIZED FOR DECOMPENSATED CHRONIC HEART FAILURE ADMITTED IN THE EMERGENCY ROOM - A FEASIBILITY STUDY

2025-521101-40-00CHRONIC DECOMPENSATED HEART FAILURE

Centre Hospitalier Regional Universitaire

Cardiovascular Diseases

France

31/03/2026

Phase IV

Non-inferiority study of TOCILIZUMAB in dose-banding versus dose-weight in rheumatoid arthritis with low activity or clinical remission

2025-522319-41-00rheumatoid arthritis

DrugTocilizumab

Centre Hospitalier Universitaire De Nice

Musculoskeletal Diseases

France

24/03/2026

Phase IV

Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis (UP-FOR-U)

2025-522118-21-00Axial Spondyloarthritis, Acute Anterior Uveitis

DrugUpadacitinib

Care Arthritis Ltd.

Eye Diseases

Spain, Poland, Netherlands, France, Bulgaria, Germany

13/03/2026

Phase IV

ILHEP : Effect of perioperative Intravenous Lidocaine on postoperative opioid related-side effects after open HEPatectomy: a multicentre prospective randomized controlled study

2025-522462-73-00Postanesthetic complications in patients undergoing open he…

DrugLidocaine

Centre Hospitalier Universitaire De Rennes

Anesthesia and Analgesia

France

10/03/2026

Phase IV

Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products

2025-521621-33-00Hepatocellular Carcinoma, Metastatic Melanoma, Melanoma, Ad…

Replimune Group Inc.

Neoplasms

Germany, Greece, France, Poland, Spain

09/02/2026

Phase IV

Efficacy of MIrikizumab to achieve traNsmural healing in patiENTs with Crohn’s Disease : EMINENT CD

2025-521889-95-00Crohn's Disease

Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif

Digestive System Diseases

France

05/02/2026

Phase IV

DOSABEMA-Pharmacokinetic model of abemaciclib: correlation with severe diarrhea as the primary toxicity endpoint in patients with hormone receptor-positive localized breast cancer

2025-521696-31-00HR+, HER2- breast cancer at high risk of recurrence

DrugAbemaciclib

Centre Hospitalier Universitaire De Poitiers

Neoplasms

France

06/01/2026

Phase IV

TRAMORNOT: Tramadol versus morphine in postoperative analgesia after laparoscopic abdominal surgery: a randomized controlled trial

2025-523327-21-00Postoperative pain following scheduled major laparoscopic a…

DrugsTramadol·Morphine

Centre Hospitalier Universitaire Amiens Picardie

Anesthesia and Analgesia

France

22/12/2025

Phase IV

Evaluation of postoperative recovery when combining intravenous lidocaine with ropivacaine infiltration in laparoscopic colorectal oncologic surgery: a randomized controlled trial

2025-523207-29-00colorectal cancer laparoscopic surgery

Centre Hospitalier Universitaire Amiens Picardie

Not possible to specify

France

17/12/2025

Phase IV

Impact of influenza vaccination on nasal resident memory immune responses and respiratory peripheral memory immune responses - MUCOVAC 2

2025-521217-46-00Adults seeking active immunisation against the seasonal inf…

Centre Hospitalier Universitaire De Saint Etienne

Virus Diseases

France

02/12/2025

Phase IV

Erector Spinae Plane Block for acute low back pain: a prospective double-blind randomized multicenter study. ESP-BACK

2024-511595-32-00Acute low back pain

DrugsKetoprofen·Tramadol·Paracetamol·Ropivacaine

Centre Hospitalier Universitaire De Montpellier

Anesthesia and Analgesia

France

26/11/2025

Phase IV

Comparison of morphine and alfentanil in the emergency treatment of severe acute pain in the pre-hospital setting

2025-522817-50-00Severe pain

DrugMorphine

CHU De Martinique

Population Characteristics

France

24/11/2025

Phase IV

Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.

2024-516232-10-00Serious infections in critically ill patients treated with …

Centre Hospitalier Universitaire De Nimes

Bacterial Infections and Mycoses

France

17/10/2025

Phase IV

Influence of patient’s morphological characteristics on pharmacokinetic and toxicity of trastuzumab-deruxtecan administered for metastatic breast cancers (TDXdose)

2025-522656-68-00Metastatic breast cancers

Oncopole Claudius Regaud

Neoplasms

France

08/10/2025

Phase IV

TIME-TO-LIA : Optimal Duration of Antibiotic Therapy in Drained Pyogenic Liver Abscess: 3 weeks versus 6 weeks, a non-inferiority trial

2025-520940-14-00Pyogenic liver abscess

DrugsDaptomycin·Colistin·Imipenem·Amikacin

Assistance Publique Hopitaux De Paris

Bacterial Infections and Mycoses

France

06/10/2025

Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 7 November 2026. https://priyalifescience.com/clinical-trials-europe/country/france

Query this register directly

GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,788 trial records at the last sync on 07 Nov 2026, 03:17 UTC; this register shows the 2,557 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 36 of those trials with a site in France that also match the filters currently applied.

How many recently authorised EU trials have a site in France?

36 of the 2,557 most recently authorised trials in this register list a site in France and match the filters applied; 0 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Summary by phase

Trials by phase (France), 36 trials
Phase	Trials	Share
Phase IV	36	100%

Most active sponsors

Lead sponsors with the most trials (France)
Lead sponsor	Trials
Assistance Publique Hopitaux De Paris	3
Centre Hospitalier Universitaire De Toulouse	3
Centre Hospitalier Universitaire Amiens Picardie	2
Centre Hospitalier Universitaire De Rennes	2
i-GETAID	2
Alk-Abello A/S	1
Boiron	1
Care Arthritis Ltd.	1
Centre Antoine Lacassagne	1
Centre De Lutte Contre Le Cancer Eugene Marquis	1

Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.